{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:56:17Z","timestamp":1782816977512,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["No.2022YFC2406900"],"award-info":[{"award-number":["No.2022YFC2406900"]}]},{"name":"Huizhi Ascent Project of Xuanwu Hospital","award":["HZ2021ZCLJ005"],"award-info":[{"award-number":["HZ2021ZCLJ005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01729-7","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:35:22Z","timestamp":1748255722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multiparametric radiomics signature for predicting molecular genotypes in adult-type diffuse gliomas utilizing 18F-FET PET\/MRI"],"prefix":"10.1186","volume":"25","author":[{"given":"Jie","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixiao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"8","key":"1729_CR1","first-page":"1073","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, et al. Glioblastoma in adults: a society for Neuro-Oncology (SNO) and European society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neurooncology. 2020;22(8):1073\u2013113.","journal-title":"Neurooncology"},{"issue":"1","key":"1729_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","volume":"21","author":"C Horbinski","year":"2023","unstructured":"Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S, et al. NCCN Guidelines\u00ae insights: central nervous system cancers, version 2.2022. J Natl Compr Cancer Netw JNCCN. 2023;21(1):12\u201320.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"9","key":"1729_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41582-022-00679-w","volume":"18","author":"C Horbinski","year":"2022","unstructured":"Horbinski C, Berger T, Packer RJ, Wen PY. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Reviews Neurol. 2022;18(9):515\u201329.","journal-title":"Nat Reviews Neurol"},{"issue":"1","key":"1729_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12325-021-01977-3","volume":"39","author":"V Di Nunno","year":"2022","unstructured":"Di Nunno V, Franceschi E, Tosoni A, Gatto L, Maggio I, Lodi R, Angelini D, Bartolini S, Brandes AA. Clinical and molecular features of patients with gliomas harboring IDH1 Non-canonical mutations: A systematic review and Meta-Analysis. Adv Therapy. 2022;39(1):165\u201377.","journal-title":"Adv Therapy"},{"issue":"8","key":"1729_CR5","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.3390\/ijms24087348","volume":"24","author":"JW Park","year":"2023","unstructured":"Park JW. Metabolic rewiring in Adult-Type diffuse gliomas. Int J Mol Sci. 2023;24(8):7348.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1729_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/biomedicines9060619","volume":"9","author":"A Vall\u00e9e","year":"2021","unstructured":"Vall\u00e9e A, Lecarpentier Y, Vall\u00e9e JN. Opposed interplay between IDH1 mutations and the WNT\/\u03b2-Catenin pathway: added information for glioma classification. Biomedicines. 2021;9(6):619.","journal-title":"Biomedicines"},{"issue":"2","key":"1729_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10014-020-00360-4","volume":"37","author":"S Ohba","year":"2020","unstructured":"Ohba S, Kuwahara K, Yamada S, Abe M, Hirose Y. Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Brain Tumor Pathol. 2020;37(2):33\u201340.","journal-title":"Brain Tumor Pathol"},{"issue":"4","key":"1729_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00432-021-03536-3","volume":"147","author":"B Powter","year":"2021","unstructured":"Powter B, Jeffreys SA, Sareen H, Cooper A, Brungs D, Po J, Roberts T, Koh ES, Scott KF, Sajinovic M, et al. Human TERT promoter mutations as a prognostic biomarker in glioma. J Cancer Res Clin Oncol. 2021;147(4):1007\u201317.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"13","key":"1729_CR9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1212\/WNL.0000000000000814","volume":"83","author":"M Labussi\u00e8re","year":"2014","unstructured":"Labussi\u00e8re M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O, Paterra R, Marie Y, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014;83(13):1200\u20136.","journal-title":"Neurology"},{"issue":"1","key":"1729_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-024-02761-7","volume":"148","author":"TE Richardson","year":"2024","unstructured":"Richardson TE, Walker JM, Hambardzumyan D, Brem S, Hatanpaa KJ, Viapiano MS, Pai B, Umphlett M, Becher OJ, Snuderl M, et al. Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant Astrocytoma. Acta Neuropathol. 2024;148(1):5.","journal-title":"Acta Neuropathol"},{"key":"1729_CR11","doi-asserted-by":"publisher","first-page":"106316","DOI":"10.1016\/j.phrs.2022.106316","volume":"182","author":"B Zhao","year":"2022","unstructured":"Zhao B, Wu J, Xia Y, Li H, Wang Y, Qu T, Xing H, Wang Y, Ma W. Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A bayesian network analysis. Pharmacol Res. 2022;182:106316.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1729_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40478-016-0351-2","volume":"4","author":"H Arita","year":"2016","unstructured":"Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016;4(1):79.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"1729_CR13","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1007\/s00259-019-04656-2","volume":"47","author":"S Song","year":"2020","unstructured":"Song S, Cheng Y, Ma J, Wang L, Dong C, Wei Y, Xu G, An Y, Qi Z, Lin Q, et al. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET\/MR improves delineation of tumor Spatial biodistribution in gliomas: a biopsy validation study. Eur J Nucl Med Mol Imaging. 2020;47(6):1458\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1729_CR14","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1007\/s00330-020-07470-9","volume":"31","author":"S Song","year":"2021","unstructured":"Song S, Wang L, Yang H, Shan Y, Cheng Y, Xu L, Dong C, Zhao G, Lu J. Static 18F-FET PET and DSC-PWI based on hybrid PET\/MR for the prediction of gliomas defined by IDH and 1p\/19q status. Eur Radiol. 2021;31(6):4087\u201396.","journal-title":"Eur Radiol"},{"issue":"4","key":"1729_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2967\/jnumed.119.234757","volume":"61","author":"GD Maurer","year":"2020","unstructured":"Maurer GD, Brucker DP, Stoffels G, Filipski K, Filss CP, Mottaghy FM, Galldiks N, Steinbach JP, Hattingen E, Langen KJ. 18F-FET PET imaging in differentiating glioma progression from Treatment-Related changes: A Single-Center experience. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2020;61(4):505\u201311.","journal-title":"Soc Nuclear Med"},{"issue":"1","key":"1729_CR16","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","volume":"25","author":"NL Albert","year":"2024","unstructured":"Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024;25(1):e29\u201341.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1729_CR17","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00259-019-04407-3","volume":"46","author":"F Liesche","year":"2019","unstructured":"Liesche F, Lukas M, Preibisch C, Shi K, Schlegel J, Meyer B, Schwaiger M, Zimmer C, F\u00f6rster S, Gempt J, et al. 18F-Fluoroethyl-tyrosine uptake is correlated with amino acid transport and neovascularization in treatment-naive glioblastomas. Eur J Nucl Med Mol Imaging. 2019;46(10):2163\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1729_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11596-022-2535-2","volume":"42","author":"S Ren","year":"2022","unstructured":"Ren S, Tang HJ, Zhao R, Duan SF, Chen R, Wang ZQ. Application of unenhanced computed tomography texture analysis to differentiate pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma. Curr Med Sci. 2022;42(1):217\u201325.","journal-title":"Curr Med Sci"},{"issue":"1","key":"1729_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2967\/jnumed.120.261545","volume":"63","author":"T Zaragori","year":"2022","unstructured":"Zaragori T, Oster J, Roch V, Hossu G, Chawki MB, Grignon R, Pouget C, Gauchotte G, Rech F, Blonski M, et al. 18F -FDOPA PET for the noninvasive prediction of glioma molecular parameters: A radiomics study. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2022;63(1):147\u201357.","journal-title":"Soc Nuclear Med"},{"key":"1729_CR20","doi-asserted-by":"publisher","first-page":"772703","DOI":"10.3389\/fonc.2021.772703","volume":"11","author":"W Zhou","year":"2021","unstructured":"Zhou W, Huang Q, Wen J, Li M, Zhu Y, Liu Y, Dai Y, Guan Y, Zhou Z, Hua T. Integrated CT radiomics features could enhance the efficacy of 18F-FET PET for Non-Invasive isocitrate dehydrogenase genotype prediction in adult untreated gliomas: A retrospective cohort study. Front Oncol. 2021;11:772703.","journal-title":"Front Oncol"},{"issue":"8","key":"1729_CR21","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1007\/s00259-024-06654-5","volume":"51","author":"L Kaiser","year":"2024","unstructured":"Kaiser L, Quach S, Zounek AJ, Wiestler B, Zatcepin A, Holzgreve A, Bollenbacher A, Bartos LM, Ruf VC, B\u00f6ning G, et al. Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [18F]FET PET, and TSPO PET. Eur J Nucl Med Mol Imaging. 2024;51(8):2371\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1729_CR22","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s00259-020-04695-0","volume":"47","author":"EK Bauer","year":"2020","unstructured":"Bauer EK, Stoffels G, Blau T, Reifenberger G, Felsberg J, Werner JM, Lohmann P, Rosen J, Ceccon G, Tscherpel C, et al. Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2020;47(6):1486\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1729_CR23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00259-023-06468-x","volume":"51","author":"X Li","year":"2024","unstructured":"Li X, Cheng Y, Han X, Cui B, Li J, Yang H, Xu G, Lin Q, Xiao X, Tang J, et al. Exploring the association of glioma tumor residuals from incongruent [18F]FET PET\/MR imaging with tumor proliferation using a multiparametric MRI radiomics nomogram. Eur J Nucl Med Mol Imaging. 2024;51(3):779\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1729_CR24","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jamaoncol.2022.2844","volume":"8","author":"TR Berger","year":"2022","unstructured":"Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World health organization 2021 classification of central nervous system tumors and implications for therapy for Adult-Type gliomas: A review. JAMA Oncol. 2022;8(10):1493\u2013501.","journal-title":"JAMA Oncol"},{"issue":"26","key":"1729_CR25","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, et al. Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499\u2013508.","journal-title":"N Engl J Med"},{"issue":"4","key":"1729_CR26","doi-asserted-by":"publisher","first-page":"e13062","DOI":"10.1111\/bpa.13062","volume":"32","author":"BT Whitfield","year":"2022","unstructured":"Whitfield BT. JT Huse.Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol. (Zurich, Switzerland). 2022;32(4):e13062.","journal-title":"Brain Pathol"},{"issue":"11","key":"1729_CR27","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2967\/jnumed.123.265642","volume":"64","author":"J Lohmeier","year":"2023","unstructured":"Lohmeier J, Radbruch H, Brenner W, Hamm B, Tietze A, Makowski MR. Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic Heterogeneity by Compartmental Uptake characteristics in Preoperative Glioma Using 18F-FET PET. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2023;64(11):1683\u20139.","journal-title":"Soc Nuclear Med"},{"issue":"12","key":"1729_CR28","first-page":"1595","volume":"21","author":"A Bashir","year":"2019","unstructured":"Bashir A, Mathilde Jacobsen S, M\u00f8lby Henriksen O, Broholm H, Urup T, Grunnet K, Andr\u00e9e Larsen V, M\u00f8ller S, Skj\u00f8th-Rasmussen J, Skovgaard Poulsen H, et al. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). Neurooncology. 2019;21(12):1595\u2013606.","journal-title":"Neurooncology"},{"issue":"3","key":"1729_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00259-017-3846-6","volume":"45","author":"A Verger","year":"2018","unstructured":"Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, Neumaier B, Shah NJ, Langen KJ, Galldiks N. Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p\/19q status. Eur J Nucl Med Mol Imaging. 2018;45(3):443\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1729_CR30","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1007\/s00259-019-04477-3","volume":"46","author":"F Vettermann","year":"2019","unstructured":"Vettermann F, Suchorska B, Unterrainer M, Nelwan D, Forbrig R, Ruf V, Wenter V, Kreth FW, Herms J, Bartenstein P, et al. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET. Eur J Nucl Med Mol Imaging. 2019;46(12):2581\u201325898.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1729_CR31","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1007\/s00330-022-08606-9","volume":"32","author":"S Song","year":"2022","unstructured":"Song S, Shan Y, Wang L, Cheng Y, Yang H, Zhao G, Wang Z, Lu J. MGMT promoter methylation status shows no effect on [18F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study. Eur Radiol. 2022;32(8):5577\u201387.","journal-title":"Eur Radiol"},{"key":"1729_CR32","doi-asserted-by":"crossref","unstructured":"Unterrainer M, Ruf V, von Rohr K, Suchorska B, Mittlmeier LM, Beyer L, Brendel M, Wenter V, Kunz WG, Bartenstein P, et al. TERT-Promoter mutational status in Glioblastoma - Is there an association with amino acid uptake on dynamic 18F-FET PET? Frontiers in oncology. 2021;11:645316.","DOI":"10.3389\/fonc.2021.645316"},{"issue":"2","key":"1729_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00259-022-05988-2","volume":"50","author":"Z Li","year":"2023","unstructured":"Li Z, Holzgreve A, Unterrainer LM, Ruf VC, Quach S, Bartos LM, Suchorska B, Niyazi M, Wenter V, Herms J, et al. Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma. Eur J Nucl Med Mol Imaging. 2023;50(2):535\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"1729_CR34","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1007\/s00259-021-05526-6","volume":"48","author":"Z Li","year":"2021","unstructured":"Li Z, Kaiser L, Holzgreve A, Ruf VC, Suchorska B, Wenter V, Quach S, Herms J, Bartenstein P, Tonn JC, et al. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics. Eur J Nucl Med Mol Imaging. 2021;48(13):4415\u201325.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1729_CR35","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1007\/s00330-019-06548-3","volume":"30","author":"M Kim","year":"2020","unstructured":"Kim M, Jung SY, Park JE, Jo Y, Park SY, Nam SJ, Kim JH, Kim HS. Diffusion- and perfusion-weighted MRI radiomics model May predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma. Eur Radiol. 2020;30(4):2142\u201351.","journal-title":"Eur Radiol"},{"issue":"1","key":"1729_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41698-021-00205-z","volume":"5","author":"J Yan","year":"2021","unstructured":"Yan J, Zhang B, Zhang S, Cheng J, Liu X, Wang W, Dong Y, Zhang L, Mo X, Chen Q, et al. Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients. NPJ Precision Oncol. 2021;5(1):72.","journal-title":"NPJ Precision Oncol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01729-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:35:23Z","timestamp":1748255723000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01729-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1729"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01729-7","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the Declaration of Helsinki, this retrospective study was approved by the Ethics Committee and Institutional Review Board of Xuanwu Hospital, Capital Medical University (No. 2023-044). Written informed consent was obtained from patients prior to PET\/MR scans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the individual and her family, who had signed the power of attorney document.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}